PRNAF — ALTERITY THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1131343 ·
Australia
Last close
$0.40
Market Cap
$87.40M
52W High
$0.55
52W Low
$0.00
ADV30
190
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 56,918,905 | 49,200,547 | 2,650,906 |
| Jun 2025 | — | — | — | — | 46,026,360 | 33,158,642 | 3,623,274 |
| Dec 2024 | — | — | — | — | 10,546,933 | 4,536,559 | 2,760,926 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,610,016
EBITDA
$-25,090,684
Free Cash Flow
$-14,740,514
Enterprise Value
$50,275,672
Total Cash
$37,317,960
Total Debt
$193,465
Shares Out
218,500,420
Trailing EPS
$-0.08
Book Value
$0.18
ROE
-55.0%
ROA
-34.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -12,333,683 | -12,147,828 | 46,026,360 | 3,623,274 | — | -11,451,248 |
| Jun 2024 | 0 | -19,402,317 | -19,123,464 | 19,223,743 | 5,425,686 | — | -12,605,824 |
| Jun 2023 | 0 | -14,368,225 | -13,806,515 | 27,317,636 | 4,504,727 | — | -20,035,837 |
| Jun 2022 | 0 | -15,137,322 | -12,847,061 | 41,362,611 | 5,894,020 | — | -12,337,274 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OSTX | OS Therapies Inc | $87.37M | $1.88 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| GOSS | Gossamer Bio, Inc. | $85.69M | $0.18 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $89.28M | $1.48 | — |
| ACET | Adicet Bio, Inc. | $89.78M | $9.59 | — |
News headlines (Yahoo Finance, 1h cache)
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
2026-09-03 11:05 · Yahoo
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
2026-08-12 11:05 · Yahoo
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
2026-08-06 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
2026-07-30 11:25 · Yahoo
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
2026-07-21 11:25 · Yahoo
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
2026-07-07 11:05 · Yahoo
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
2026-06-09 11:05 · Yahoo
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
2026-05-19 11:25 · Yahoo
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
2026-05-11 11:25 · Yahoo
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
2026-05-07 11:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.